Licensing Programs

New Drug Candidates

In- and out-licensing of clinical-stage assets from preclinical through Phase III — matched on therapeutic fit, territory rights and development stage, and screened for registration and reimbursement before the term sheet.

Submit a Project Search the database

New Drug Candidates

Unibest partners with numerous biotech and pharmaceutical firms around the world, facilitating the successful in-licensing and out-licensing of intellectual property (IP) at every stage of new drug development and commercialization. Our core mission is to connect global pharmaceutical resources, helping to create a healthier future for all.

View all pipelines

Core Business

Six stages, run in the order that kills a bad idea cheaply and builds confidence in a good one.

Project screening

The asset, indication, development stage and territory ambition are established, along with what a successful deal would have to look like commercially. A vague brief produces a long shortlist that helps nobody.

AI-assisted matching

Candidates are drawn from the customer matrix and constrained by what the product matrix says about crowding and exclusivity in each target market. Each name arrives with a stated rationale, not just a logo.

Registration pathway planning

Filing routes are assessed against the intended launch sequence. A gap analysis establishes what the existing data package supports, which is what turns a hoped-for timeline into a defensible one.

HTA pre-assessment

Comparator expectations, endpoint acceptability and the pricing environment are screened per market. A product can be approvable and still commercially dead, and that is worth knowing before the valuation is agreed.

Transaction execution

Terms, milestones, territory carve-outs and responsibility splits are negotiated, and the agreements are drafted or reviewed so that obligations on both sides are unambiguous.

Post-deal implementation

Filing, technology transfer, supply setup and launch support continue under the same program plan, so the asset actually reaches the market rather than stalling after signature.

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here